Ask AI

Unlocking the Full Potential of HER2-Directed ADCs in HER2-Mutant and Overexpressing Lung Cancer: Testing Applications, Data Insights, and Effective Decision-making for Patient-Centric Care

Improve your understanding of HER2-directed ADCs for the management of your patients with HER2-mutant and HER2 overexpressing NSCLC based on the latest clinical data and guidelines to implement personalized treatment plans through microlearning video modules, a certified text module, expert-authored commentaries, and accompanying downloadable slides.

Share

Program Content

Activities

Targeting HER2 in NSCLC
Rationale for Targeting HER2 in NSCLC, Optimal Testing Strategies, and Data on HER2-Directed ADCs in NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2026

Expires: August 03, 2026

Practical Applications of and Emerging HER2 Targeted Approaches
Practical Applications of HER2-Targeted Therapy and Emerging HER2-Directed Approaches
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2026

Expires: August 03, 2026

Activities

Targeting HER2 in NSCLC
HER2 in Context in NSCLC, Testing Strategies and Advances in Methodologies, and a Brief Review of ADCs in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2025

HER2 Directed ADCs in NSCLC
Data on HER2-Targeted Therapies in NSCLC, Practical Applications of HER2-Targeted Therapy, and Management of Treatment-Emergent Adverse Events
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2025

Activities

HER2 Directed ADCs in NSCLC
Evolving Role of HER2-Directed Antibody–Drug Conjugates in the Management of Patients With Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.